Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines

References

• Heppner K. J., Matrisian L. M., Jensen R. A., Rodgers W. H. Expression of most matrix 1 metalloproteinase family members in breast cancer represents a tumor‐induced host response. Am J Pathol 1996; 149: 273–82
   PubMed Web of Science ®Google Scholar
• Dickson R. B., Shi Y. E., Johnson M. D. Matrix‐degrading proteases in hormone‐dependent breast cancer. Breast Cancer Res Treat 1994; 31: 167–73
   PubMed Web of Science ®Google Scholar
• Shinmei M., Masuda K., Kikuchi T., Shimomura Y. J. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl 1989; 18: 32–4
   PubMedGoogle Scholar
• Duncan M. R., Berman B. Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon‐alpha, ‐beta, and ‐gamma. Arch Dermatol Res 1989; 281: 11–18
   PubMed Web of Science ®Google Scholar
• Vollberg T. M., George M. D., Jetten A. M. Induction of extracellular matrix gene expression in normal human keratinocytes by transforming growth factor beta is altered by cellular differentiation. Exp Cell Res 1991; 193: 93–00
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh N., Shingu M., Nobunaga M. The effect of recombinant tumor necrosis factor‐alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8: 387–91
   PubMed Web of Science ®Google Scholar
• Unemori E. N., Hibbs M. S., Amento E. P. Constitutive expression of a 92‐kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J Clin Invest 1991; 88: 1656–62
   PubMed Web of Science ®Google Scholar
• Owen C. A., Hu Z., Lopez‐Otin C., Shapiro S. D. Membrane‐bound matrix metalloproteinase‐8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase‐resistant collagenases and serpinase. J Immunol 2004; 172: 7791–803
   PubMed Web of Science ®Google Scholar
• Sorsa T., Golub L. M. Is the excessive inhibition of matrix metalloproteinases (MMPs) by potent synthetic MMP inhibitors (MMPIs) desirable in periodontitis and other inflammatory diseases? ie., “leaky” MMPIs vs. excessively efficient drugs. Oral Dis. 2005; accepted for publication
   Google Scholar
• Golub L. M., Lee H. M., Ryan M. E., Giannobile W. V., Payne J., Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non‐antimicrobial mechanisms. Adv Dent Res 1998; 12: 12–26
   PubMedGoogle Scholar
• Zucker S., Lysik R. M., Ramamurthy N. S., Golub L. M., Wieman J. M., Wilkie D. P. Diversity of melanoma plasma membrane proteinases: inhibition of collagenolytic and cytolytic activities by minocycline. J Natl Cancer Inst 1985; 75: 517–25
   PubMed Web of Science ®Google Scholar
• Zucker S., Wieman J., Lysik R. M., Imhof B., Nagase H., Ramamurthy N. S. Gelatin‐degrading type IV collagenase isolated from human small cell lung cancer. Invasion Metastasis 1989; 9: 167–81
   PubMedGoogle Scholar
• Rifkin B. R., Vernillo A. T., Golub L. M., Ramamurthy N. S. Modulation of bone resorption by tetracyclines. Ann N Y Acad Sci 1994; 732: 165–80
   PubMed Web of Science ®Google Scholar
• Lokeshwar B. L., Selzer M. G., Zhu B. Q., Block N. L., Golub L. M. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non‐antimicrobial tetracycline analog (COL‐3) in a metastatic prostate cancer model. Int J Cancer 2002; 98: 297–309
   PubMed Web of Science ®Google Scholar
• Ramos‐DeSimone N., Hahn‐Dantona E., Sipley J., Nagase H., French D. L., Quigley J. P. Activation of matrix metalloproteinase‐9 (MMP‐9) via a converging plasmin/stromelysin‐1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066–76
   PubMed Web of Science ®Google Scholar
• Rinehart A. R., Mallya S., Simon S. R. Human alpha 1‐proteinase inhibitor binds to extracellular matrix in vitro. Am J Respir Cell Mol Biol 1993; 9: 666–79
   PubMed Web of Science ®Google Scholar
• Gu Y., Lee H. M., Roemer E. J., Musacchia L., Golub L. M., Simon S. R. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem 2001; 8: 261–70
   PubMed Web of Science ®Google Scholar
• Roemer E. J., Stanton K., Simon S. R. In vitro assay systems for cell interactions with intersititial extracellular matrix. In Vitro Toxicology 1994; 7: 209–24
   Google Scholar
• Fidler I. J., Radinsky R. J. Genetic control of cancer metastasis. J Natl Cancer Inst 1990; 82: 166–8
   PubMedGoogle Scholar
• Liotta L. A., Steeg P. S., Stetler‐Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–36
   PubMed Web of Science ®Google Scholar
• Akiyama S. K., Nagata K., Yamada K. M. Cell surface receptors for extracellular matrix components. Biochim Biophys Acta 1990; 1031: 91–110
   PubMed Web of Science ®Google Scholar
• Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11–25
   PubMed Web of Science ®Google Scholar
• Kozlova N. I., Morozevich G. E., Soloveyva N. I., Vinokurova S. V., Berman A. E. Integrin expression and collagenase activity of RSV‐transformed Syrian hamster fibroblasts, differing in spontaneous metastasizing. Biochem Mol Biol Int 1997; 43: 529–39
   PubMedGoogle Scholar
• Langholz O., Rockel D., Mauch C., Kozlowska E., Bank I., Krieg T. Collagen and collagenase gene expression in three‐dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. Cell Biol 1995; 131: 1903–15
   PubMed Web of Science ®Google Scholar
• Smith G. N., Brandt K. D., Hasty K. A. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline. Ann N Y Acad Sci 1994; 732: 436–8
   PubMed Web of Science ®Google Scholar
• Uitto V. J., Firth J. D., Nip L., Golub L. M. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP‐2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 1994; 732: 140–51
   PubMed Web of Science ®Google Scholar
• Mackay A. R., Ballin M., Pelina M. D., Farina A. R., Nason A. M., Hartzler J. L. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992; 12: 168–84
   PubMedGoogle Scholar
• Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson. Processing of tumour necrosis factor‐alpha precursor by metalloproteinases. Nature 1994; 370: 555–7
   PubMed Web of Science ®Google Scholar
• Mohler K. M., Sleath P. R., Fitzner J. N., Cerretti D. P., Alderson M., Kerwar S. S. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218–20
   PubMed Web of Science ®Google Scholar
• Moss M. L., Jin S. L., Milla M. E., Bickett D. M., Burkhart W., Carter. Cloning of a disintegrin metalloproteinase that processes precursor tumour‐necrosis factor‐alpha. Nature 1997; 385: 733–6
   PubMed Web of Science ®Google Scholar
• Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F. A metalloproteinase disintegrin that releases tumour‐necrosis factor‐alpha from cells. Nature 1997; 385: 729–33
   PubMed Web of Science ®Google Scholar
• Amour A., Slocombe P. M., Webster A., Butler M., Knight C. G., Smith B. J. TNF‐alpha converting enzyme (TACE) is inhibited by TIMP‐3. FEBS Lett 1998; 435: 39–44
   PubMed Web of Science ®Google Scholar
• Overall C. M., Lopez‐Otin C. Strategies for MMP inhibition in cancer: innovations for the post‐trial. Nat Rev Cancer 2002; 2: 657–72
   PubMed Web of Science ®Google Scholar